Since then, Odyssey has had no problems bringing in the megarounds. As well as the $218 million that the company launched ...

Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...

While GLP-1s like Ozempic and Wegovy are being widely prescribed for weight loss, doctors currently do not have a way to ...

Entrada identified lower-than-expected plasma exposure in juvenile DMD patients as the cause of the lackluster data. Exposure ...

Banyan BioInnovations is debuting with more than $100 million aimed at developing independent companies for promising clinical-stage treatments, plus a partnership with global contract research ...

Ascendis Pharma has ended internal development of its IL-2 candidate, pivoting away from oncology and calling time on an ...

Gilead will lay off 108 workers from Arcellx’s site at 800 Bridge Parkway in Redwood City, CA, according to a Worker ...

Roche is set to pay out $750 million upfront to acquire digital pathology specialist Path AI in a move by the pharma giant to accelerate the use of artificial intelligence in diagnostic algorithms.

BeOne Medicines has shaken up its early pipeline, dropping five phase 1 cancer programs and stopping a phase 2 arthritis ...

Leerink Partners analysts slashed their sales forecast for enGene Therapeutics’ bladder cancer candidate after phase 2 data ...

A phase 2 trial of Avalo Therapeutics’ hidradenitis suppurativa (HS) candidate hit its primary endpoint, emboldening the ...

The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that Perfuse ...